Tvardi Therapeutics
TVRD
56 hedge funds and large institutions have $81.5M invested in Tvardi Therapeutics in 2014 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
14% more funds holding
Funds holding: 49 → 56 (+7)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
45% less capital invested
Capital invested by funds: $149M → $81.5M (-$67.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$4.37M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.78M |
| 3 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
+$1.71M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.69M |
| 5 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.25M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.74M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$760K |
| 4 |
Jennison Associates
New York
|
-$712K |
| 5 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$656K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $2K | +$1.23K | +3 | +150% |
|
52
Barclays
London,
United Kingdom
| $1K | +$1.23K | +3 | +150% |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| $1K | +$1.64K | +4 | New |
|
54
BNP Paribas Financial Markets
Paris,
France
| $998 | -$2.05K | -5 | -63% |
|
55
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $24 | +$15.2K | +37 | +84% |
|
|
CCM
56
Cadence Capital Management
Boston,
Massachusetts
| – | -$656K | -1,071 | Closed |
|
57
Charles Schwab
San Francisco,
California
| – | -$215K | -351 | Closed |
|
|
BPC
58
Banque Pictet & Cie
Geneva 73,
Switzerland
| – | -$171K | -280 | Closed |
|
|
GGHC
59
Gilder Gagnon Howe & Co
New York
| – | -$158K | -257 | Closed |
|
60
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$30K | -73 | -99% |
|
|
VFA
61
Virtus Fund Advisers
Hartford,
Connecticut
| – | -$8K | -13 | Closed |
|
62
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$2K | -4 | Closed |
|
|
GC
63
Globeflex Capital
San Diego,
California
| – | -$1K | -2 | Closed |
|
TVRD Hedge Fund Activity: Q3 2014 in Review
56 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2014, worth a combined $81.5M — down 45% from $149M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TVRD positions and 7 closed out — a net gain of 7 holders — while 15 added to existing stakes and 16 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $4.37M. The largest seller was Fidelity Investments, cutting an estimated $3.25M.
- 56 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2014, up from 49 in Q2 2014.
- Funds reported $81.5M of Tvardi Therapeutics stock for Q3 2014, down 45% quarter-over-quarter.
- 14 funds opened new Tvardi Therapeutics positions in Q3 2014 and 7 closed out, a net change of +7 holders.
- The largest Tvardi Therapeutics buyer in Q3 2014 was Deerfield Management, an estimated $4.37M added.
- The largest Tvardi Therapeutics seller in Q3 2014 was Fidelity Investments, an estimated $3.25M sold.
Based on aggregated 13F filings for Q3 2014.